Core Insights - Neurocrine Biosciences presented head-to-head data showing that INGREZZA (valbenazine) has significantly higher VMAT2 target occupancy compared to AUSTEDO XR (deutetrabenazine), indicating greater potency in treating hyperkinetic movement disorders [1][3][7] Group 1: Study Findings - The study confirmed that both INGREZZA and AUSTEDO XR engage VMAT2, but INGREZZA demonstrated approximately two-fold higher target occupancy at therapeutic doses [3][4] - The primary analysis showed a least squares mean VMAT2 occupancy of approximately 76.5% for INGREZZA compared to 38.3% for AUSTEDO XR [3][4] - Pharmacokinetic modeling indicated superior VMAT2 engagement at therapeutic doses for INGREZZA, with estimated steady-state occupancy of 83% at 40 mg and 92% at 80 mg, compared to AUSTEDO XR's 54% at 24 mg and 70% at 48 mg [4] Group 2: Clinical Implications - The higher VMAT2 occupancy of INGREZZA may contribute to its robust clinical efficacy observed in multiple trials for tardive dyskinesia and Huntington's disease chorea [3][4] - Both INGREZZA and AUSTEDO XR were generally well tolerated, consistent with their known safety profiles [5] Group 3: Background on Disorders - Tardive dyskinesia (TD) is characterized by uncontrolled movements and affects at least 800,000 adults in the U.S., often as a side effect of antipsychotic medications [8] - Huntington's disease (HD) affects approximately 41,000 adults in the U.S. and is associated with chorea, an involuntary movement disorder [9] Group 4: Product Information - INGREZZA is a selective VMAT2 inhibitor approved for treating adults with tardive dyskinesia and chorea associated with Huntington's disease, offering therapeutic doses from day one without required titration [10][11] - The product is available in capsule forms of 40 mg, 60 mg, and 80 mg, and also in a sprinkle formulation for patients with swallowing difficulties [12][23]

Core Insights - Neurocrine Biosciences presented a post-hoc analysis from the Phase 3 KINECT 4 study, showing that continuous treatment with INGREZZA (valbenazine) at a 40 mg dose for 48 weeks led to significant improvements in tardive dyskinesia (TD) symptoms [1][5][6] Study Findings - The KINECT 4 study demonstrated that 90% of participants who completed 48 weeks of treatment with INGREZZA 40 mg achieved a 50% improvement in the Abnormal Involuntary Movement Scale (AIMS) total score [5][6] - Efficacy was assessed through clinician- and patient-reported measures, with sustained improvements observed throughout the treatment period [4][6] - The analysis included 45 patients on the 40 mg dose and 11 patients who escalated to 80 mg before reducing back to 40 mg, showing similar therapeutic benefits [3][6] Safety and Tolerability - The safety profile of INGREZZA remained consistent with previous studies, with most treatment-emergent adverse events being mild to moderate [4][9] - Common side effects included sleepiness and tiredness, with no new safety concerns identified during the study [4][20] Treatment Flexibility - INGREZZA is unique as the only VMAT2 inhibitor that allows patients to start at a therapeutic dose without the need for titration, providing flexibility in dosing based on individual response and tolerability [2][10]